Search Results - "Coco, Paola"

P686: REAL‐WORLD EFFICACY PROFILE OF ASCIMINIB IN AN ITALIAN, MULTI‐RESISTANT CHRONIC‐PHASE CHRONIC MYELOID LEUKEMIA (CP‐CML) PATIENT POPULATION by Breccia, Massimo, Russo Rossi, Antonella, Giai, Valentina, Martino, Bruno, Fava, Carmen, Annunziata, Mario, Abruzzese, Elisabetta, Binotto, Gianni, Baratè, Claudia, Pio Nardozza, Aurelio, Misto, Alessandra, Coco, Paola, Calafiore, Valeria, Cristina Carraro, Maria, Cattina, Federica, Cavazzini, Francesco, Teresa Corsetti, Maria, Crucitti, Lara, Crugnola, Monica, Ditonno, Paolo, DI Veroli, Ambra, Ermacora, Anna, Ferrara, Felicetto, Genua, Angelo, Gozzini, Antonella, Impera, Stefana, Iurlo, Alessandra, Levato, Luciano, Luciano, Luigiana, Cristina Miggiano, Maria, De Gobbi, Marco, Santoro, Marco, Scappini, Barbara, Rita Scortechini, Anna, Patriarca, Andrea, Rosati, Serena, Russo, Sabina, Sancetta, Rosaria, Sanpaolo, Grazia, Maria Santeramo, Teresa, Sibilla, Silvia, Sorà, Federica, Sportoletti, Paolo, Stagno, Fabio, Trabacchi, Elena, Castagnetti, Fausto

Get full text

A Phase II, Single-Arm Study of De-Escalation and Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line Therapy Followed By a Second Attempt after Nilotinib and Asciminib Combination: Dante Study by Rosti, Gianantonio, Saglio, Giuseppe, Stagno, Fabio, Valsecchi, Diletta, Nardozza, Aurelio Pio, Coco, Paola, Breccia, Massimo, Iurlo, Alessandra

Get full text

Full Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study by Iurlo, Alessandra, Breccia, Massimo, Stagno, Fabio, Abruzzese, Elisabetta, Pane, Fabrizio, Attolico, Immacolata, Sportoletti, Paolo, Cerrano, Marco, Galimberti, Sara, Scappini, Barbara, Miglino, Maurizio, Siragusa, Sergio, Capodanno, Isabella, Valsecchi, Diletta, Nardozza, Aurelio Pio, Misto, Alessandra, Coco, Paola, Saglio, Giuseppe, Rosti, Gianantonio

“…Introduction: Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is achievable and recommended for patients (pts) in sustained deep molecular…”
Get full text

Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST by GRONCHI, Alessandro, FIORE, Marco, MISELLI, Francesca, LAGONIGRO, Maria Stefania, COCO, Paola, MESSINA, Antonella, PILOTTI, Silvana, CASALI, Paolo Giovanni

“…To explore the role of surgery of residual disease following a period of therapy with imatinib mesylate in advanced gastrointestinal stromal tumors (GIST)…”
Get full text

Real-World Analysis of the Clinical and Economic Burden of Later Line in Chronic Myeloid Leukemia Patients in Italy by Breccia, Massimo, Chiodi, Francesca, Valsecchi, Diletta, Perrone, Valentina, Sangiorgi, Diego, Giacomini, Elisa, Rendace, Maria Chiara, Coco, Paola, Premoli, Eleonora, Degli Esposti, Luca

“…Background The use of real-world data in oncology is gaining increasing interest, as it can provide valuable insights into treatments and related outcomes in…”
Get full text

Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study by Stagno, Fabio, Abruzzese, Elisabetta, Iurlo, Alessandra, Pane, Fabrizio, Attolico, Imma, Sportoletti, Paolo, Pregno, Patrizia, Galimberti, Sara, Scappini, Barbara, Miglino, Maurizio, Siragusa, Sergio, Capodanno, Isabella, Valsecchi, Diletta, Nardozza, Aurelio Pio, Coco, Paola, Rosti, Gianantonio, Saglio, Giuseppe, Breccia, Massimo

Get full text

The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy by Breccia, Massimo, Chiodi, Francesca, Nardozza, Aurelio Pio, Valsecchi, Diletta, Perrone, Valentina, Sangiorgi, Diego, Giacomini, Elisa, Rendace, Maria Chiara, Coco, Paola, Premoli, Eleonora, Degli Esposti, Luca

“…Introduction Chronic myeloid leukemia (CML) is a hematopoietic myeloproliferative disorder that accounts for 20% of all leukemias of adults. The introduction…”
Get full text

Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI) by Guglielmelli, Paola, Palandri, Francesca, Selleri, Carmine, Cilloni, Daniela, Mendicino, Francesco, Mazza, Patrizio, Pastore, Domenico, Palumbo, Giuseppe A., Santoro, Marco, Pavone, Vincenzo, Impera, Stefana, Morelli, Mara, Coco, Paola, Valsecchi, Diletta, Passamonti, Francesco, Breccia, Massimo

“…ROMEI, a prospective, observational study in patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib in real-world practice, assesses…”
Get full text

Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy by Breccia, Massimo, Chiodi, Francesca, Nardozza, Aurelio Pio, Valsecchi, Diletta, Perrone, Valentina, Sangiorgi, Diego, Giacomini, Elisa, Rendace, Maria Chiara, Coco, Paola, Premoli, Eleonora, Degli Esposti, Luca

“…Real world data are becoming a crucial tool to understand how cancer is treated in routine daily practice. This real-world analysis aims to describe the…”
Get full text

Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study by Ferrucci, Pier F, Minchella, Ida, Mosconi, Massimo, Gandini, Sara, Verrecchia, Francesco, Cocorocchio, Emilia, Passoni, Claudia, Pari, Chiara, Testori, Alessandro, Coco, Paola, Munzone, Elisabetta

“…The combined treatment of dacarbazine with an antiangiogenic drug such as bevacizumab may potentiate the therapeutic effects of dacarbazine in metastatic…”
Get full text

Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib by Italiano, Antoine, Cioffi, Angela, Coco, Paola, Maki, Robert G., Schöffski, Patrick, Rutkowski, Piotr, Le Cesne, Axel, Duffaud, Florence, Adenis, Antoine, Isambert, Nicolas, Bompas, Emmanuelle, Blay, Jean-Yves, Casali, Paolo, Keohan, Mary Louise, Toulmonde, Maud, Antonescu, Cristina R., Debiec-Rychter, Maria, Coindre, Jean-Michel, Bui, Binh

“…Background Data regarding the management and outcome of patients with metastatic gastrointestinal stromal tumors (GIST) refractory to 1st-line imatinib and…”
Get full text

A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake by Mannavola, Deborah, Coco, Paola, Vannucchi, Guia, Bertuelli, Rossella, Carletto, Marco, Casali, Paolo G., Beck-Peccoz, Paolo, Fugazzola, Laura

“…Context: Sunitinib (sunitinib malate; SU11248; Sutent; Pfizer Inc., New York, NY) is a multitarget inhibitor of tyrosine kinases for the treatment of some…”
Get full text

JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy by Vannucchi, Alessandro Maria, Mortara, Andrea, D’Alessio, Andrea, Morelli, Mara, Tedeschi, Alberto, Festuccia, Moreno Benedetto, Monforte, Antonella D’Arminio, Capochiani, Enrico, Selleri, Carmine, Simonetti, Federico, Saracino, Annalisa, Rapezzi, Davide, Badagliacca, Maria Rita, Falasca, Katia, Molteni, Alfredo, Palazzolo, Roberto, Schettino, Giuliano, Bocchia, Monica, Turrini, Mauro, Ascierto, Paolo A., Zuurman, Mike, Paley, Carole, Coco, Paola, Saglio, Giuseppe

“…Jak inhibitors are potent anti-inflammatory drugs that have the potential to dampen the hyperactive inflammatory response associated with severe COVID-19. We…”
Get full text

Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study by Dileo, Palma, Pricl, Sabrina, Tamborini, Elena, Negri, Tiziana, Stacchiotti, Silvia, Gronchi, Alessandro, Posocco, Paola, Laurini, Erik, Coco, Paola, Fumagalli, Elena, Casali, Paolo G., Pilotti, Silvana

“…Beside the well known “in vivo” and “in vitro” Imatinib resistant D842V mutation in PDGFRA receptor, very few are the information concerning the “in vivo”…”
Get full text